Sun Pharma Advanced Research Co (NSE:SPARC) PEG Ratio: N/A (As of Jul. 04, 2026)


NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
61 GF Score
Price ₹239.37
GF Value ₹4,504.88
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Sun Pharma Advanced Research Co's PE Ratio without NRI is 4.97. Sun Pharma Advanced Research Co's 5-Year EBITDA growth rate is 0.00%. Therefore, Sun Pharma Advanced Research Co's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Sun Pharma Advanced Research Co's PEG Ratio or its related term are showing as below:



NSE:SPARC's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.71
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Sun Pharma Advanced Research Co  (NSE:SPARC) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Sun Pharma Advanced Research Co PEG Ratio Related Terms


Sun Pharma Advanced Research Co PEG Ratio Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co PEG Ratio Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sun Pharma Advanced Research Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:SPARC vs ZTS, UTHR: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Pharma Advanced Research Co PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's PEG Ratio falls into.


NSE:SPARC
61GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Sun Pharma Advanced Research Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=4.9747490491926/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹239.37 is trading 94.7% below its estimated GF Value™ of ₹4,504.88. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • PEG Ratio: N/A
  • GF Value™: ₹4,504.88 vs. price of ₹239.37 (94.7% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
61GF Score

Get the complete analysis for NSE:SPARC

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹239.37
Price
₹4,504.88
GF Value